{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=55&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=56&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=54&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T01:49:35.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04606771",
      "title": "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib + Savolitinib",
          "type": "DRUG"
        },
        {
          "name": "Savolitinib + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-09-28",
      "completion_date": "2027-03-15",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Sacramento, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04606771"
    },
    {
      "nct_id": "NCT05963009",
      "title": "Baxdrostat Bioavailability and Bioequivalence Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "baxdrostat (formerly CIN-107) oral solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2020-03-11",
      "completion_date": "2020-04-29",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05963009"
    },
    {
      "nct_id": "NCT03330847",
      "title": "To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib Continuous (28-Day cycle) 300 mg BD.",
          "type": "DRUG"
        },
        {
          "name": "Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).",
          "type": "DRUG"
        },
        {
          "name": "Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 273,
      "start_date": "2018-03-07",
      "completion_date": "2026-10-09",
      "has_results": true,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330847"
    },
    {
      "nct_id": "NCT02901548",
      "title": "Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma in Situ of Bladder",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cystoscopy with Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-02-16",
      "completion_date": "2021-09-07",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 2,
      "location_summary": "Miami Beach, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02901548"
    },
    {
      "nct_id": "NCT00738725",
      "title": "BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Plaque",
        "Atherosclerotic Disease",
        "Heart Disease",
        "Stroke"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "BG Medicine, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 7687,
      "start_date": "2008-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 2,
      "location_summary": "Oakland Park, Florida • Justice, Illinois",
      "locations": [
        {
          "city": "Oakland Park",
          "state": "Florida"
        },
        {
          "city": "Justice",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738725"
    },
    {
      "nct_id": "NCT02601625",
      "title": "A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety",
        "Pharmacokinetics",
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Anifrolumab SC injection (300mg)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab IV infusion (300mg)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab SC infusion (600mg)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab placebo SC injection (300mg)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab placebo IV infusion (300mg)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab placebo SC infusion (600mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-11-16",
      "completion_date": "2016-05-25",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601625"
    },
    {
      "nct_id": "NCT02983578",
      "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Colorectal Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Mismatch Repair Deficiency",
        "Refractory Colorectal Carcinoma",
        "Refractory Lung Carcinoma",
        "Refractory Pancreatic Carcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Danvatirsen",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2017-03-02",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983578"
    },
    {
      "nct_id": "NCT06040099",
      "title": "A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma (HCC)"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Transarterial Radioembolization (TARE)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 58,
      "start_date": "2024-02-13",
      "completion_date": "2027-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 21,
      "location_summary": "Aurora, Colorado • Gainesville, Florida • Orlando, Florida + 16 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06040099"
    },
    {
      "nct_id": "NCT00473616",
      "title": "Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Cancer",
        "Advanced Solid Malignancies"
      ],
      "interventions": [
        {
          "name": "AZD7762",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-05",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2011-02-11",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473616"
    },
    {
      "nct_id": "NCT00985933",
      "title": "The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Memory Impairment"
      ],
      "interventions": [
        {
          "name": "AZD8529",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match AZD8529",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-02",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2011-05-04",
      "last_synced_at": "2026-11-04T01:49:35.454Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985933"
    }
  ]
}